Akebia Therapeutics (AKBA) Misses Q4 EPS by 32c

Akebia Therapeutics (NASDAQ: AKBA) reported Q4 EPS of ($0.79), $0.32 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $69.56 million versus the consensus estimate of $93.15 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• MP Materials seen largely insulated after China export-control move